An observational study from a single pharmacy found that of the 74 patients prescribed xanthine oxidase inhibitors, the indications for treatment were gout in 60.8%, asymptomatic hyperuricemia in 33.8%, and uric acid nephrolithiasis in 5.4% [35]. This evidence concerns the gene XDH and Uric acid nephrolithiasis.